Tech Nation
Sundays, 6 a.m. - 7 a.m.
In 2004, Gunn added a regular segment on biotechnology, BioTech Nation. It has emerged as the only regular weekly mainstream programming on biotech on the national and international scene, and features interviews with biotech leaders. In its regular feature: “BioIssue of the Week”, Gunn discusses the breaking news of the day with award-winning science journalist, David Ewing Duncan.
In the U.S., Tech Nation can be heard four times each weekend on the National Public Radio website’s 24-hour Program Stream (npr.org). It airs on nearly 200 public radio stations, with multiple airtimes on the NPR Channels on XM-Sirius Satellite Radio. Globally, Tech Nation is aired three times weekly on the NPR Channels of Sirius Internet Radio and airs 25 weekly to 177 countries via Armed Forces Radio International. Tech Nation podcasts remain permanently archived on the Internet, enabling anyone, anywhere to listen to these materials on demand.
Most Recent Episodes
-
This week on BioTech Nation, BioSTEM Technologies CEO Jason Matuszewski explains how donated placental tissue is being used to treat chronic wounds that just won’t heal, from diabetic ulcers to pressure sores. With millions affected and traditional care often falling short, BioSTEM’s approach offers a new way to support healing and reduce scarring.
-
This week on BioTech Nation, Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antivenom vaccine in 125 years.
-
This week on BioTech Nation, Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, returns with highlights from the 2025 NextMed Health conference. From AI-powered health agents to voice-based disease detection, hear what’s emerging at the intersection of medicine, technology, and global health equity.
-
Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.
-
This week on BioTech Nation, Dr. Cory Nicholas, CEO of Neurona Therapeutics, returns for part two. With early results now in from Neurona’s first clinical trial, patients with severe epilepsy are seeing dramatic improvements, including seizure reductions of over 90 percent, and even full remission in some cases. This one-time treatment delivers new brain cells that help calm seizure activity without the side effects of traditional medications or the risks of surgery.
-
PART 1: A Regenerative Leap for Epilepsy…Dr. Cory Nicholas, Co-Founder and CEO, Neurona TherapeuticsThis week on BioTech Nation, Dr. Cory Nicholas, Co-Founder and CEO of Neurona Therapeutics, discusses their groundbreaking success in treating drug-resistant epilepsy. With a single, targeted delivery of lab-grown brain cells, Neurona is offering not just symptom control but the possibility of long-term seizure relief. This is Part 1 of a two-part series exploring the future of regenerative medicine in neurology.
-
This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.
-
This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.
-
This week on BioTech Nation, Luminary Therapeutics CEO Jeff Liter shares how his team is working to make advanced cell therapy easier to access and more affordable. Instead of using each patient’s own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose.
-
This week on BioTech Nation, Sean Ainsworth, CEO of ImmuSoft, explains how modifying the body’s own B cells to produce therapeutic proteins could revolutionize drug delivery. From improving treatment for rare diseases like Hurler syndrome to potentially replacing injections for autoimmune and metabolic conditions, this new approach opens the door to long-term, patient-specific solutions.